Global Mycoplasma Testing Market Driven by Increasing Stringent...

Global Mycoplasma Testing Market Driven by Increasing Stringent Regulations

Posted 2024-05-28 11:09:10

The Global Mycoplasma Testing Market involves screening and identification of mycoplasma contamination in a variety of sample types including cell lines, tissues, and other biological products. Mycoplasma testing provides key advantages such as detection of latent and slow-growing mycoplasma, high sensitivity and specificity toward a variety of mycoplasma species. The need for mycoplasma testing has increased significantly owing to stringent regulations and product quality pertaining to biosafety.

The Global Mycoplasma Testing Market is estimated to be valued at US$ 997.8 Mn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 To 2031.

Key Takeaways

Key players: Key players operating in the Global Mycoplasma Testing market are Charles River Laboratories International, Merck KGaA, Lonza Group Ltd, Roche Diagnostics, Thermo Fisher Scientific, Merck, InvivoGen, Creative Bioarray. These players are focusing on new product launches and growth strategies such as mergers and acquisitions to gain market share.

Growing demand: Global Mycoplasma Testing Market Size Rapid advancements in biologics and cell therapy have propelled the demand for mycoplasma testing. Furthermore, ongoing R&D in pharmaceutical and biotechnology industries has augmented market growth.

Global expansion: Leading players are expanding their geographical footprints in emerging nations of Asia Pacific and Latin America. Increasing biotech start-ups and contract research organizations in these regions are creating new revenue streams.

Market drivers: Stringent regulatory compliance pertaining to biosafety is a key factor driving the mycoplasma testing market. Mandates requiring mycoplasma screening prior to product approval and distribution have increased exponentially. Rapid automation and adoption of new detection technologies are also fueling market revenues.